Q-omics provides the consensus-scored MAX profile across patient tissues and cancer cell-line models. MAX expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MAX is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MAX protein abundance shows 24,234 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRC, and GBM as cancer lineages where MAX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAX survival associations across molecular data types. MAX RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAX RNA expression–survival associations across cancer types. High MAX expression shows unfavorable associations in ACC and KICH, but favorable associations in BRCA, MESO, LUSC and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for MAX RNA expression.
This table summarizes MAX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAX shows lower tumor expression in UCEC and higher tumor expression in KIRC, LIHC, KIRP, CHOL and BRCA. The KIRC box plot shows higher MAX RNA expression in tumor versus normal tissue (log2 FC = +0.506, t-test p < 0.001).
This table shows molecular features associated with MAX in patient tissues and cancer cell lines. In patient samples, MAX shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
